Jonjić Stipan, akademik

Redoviti članovi III. Razred za prirodne znanosti
Jonjić Stipan

Datum rođenja:

  • 1953.

Mjesto rođenja:

  • Kupres

Adrese:

  • Centar za proteomiku, Medicinski fakultet Sveučilišta u Rijeci, Braće Branchetta 20, 51 000 Rijeka

Telefoni:

  • Centar za proteomiku, Medicinski fakultet u Rijeci: +385 051 651 162

E-mail adrese:

Jonjić Stipan, akademik

Redoviti članovi III. Razred za prirodne znanosti

Institucije:

  • voditelj – Centar za proteomiku, Medicinski fakultet Sveučilišta u Rijeci

Funkcije u Akademiji:

  • voditelj – Zavod za biomedicinske znanosti (6.7.2022. – …)

Članstvo u Akademiji:

  • redoviti član – Razred za prirodne znanosti (19.05.2022. – …)

Životopis

Stipan Jonjić – osobna stranica

 

Školovanje

1985. dr. sc., Medicinski falultet Sveučilišta u Rijeci

1976. dr. med., Medicinski falultet Sveučilišta u Rijeci

Trenutno zaposlenje

    1. – Redoviti profesor u trajnom zvanju i predstojnik, Centar za proteomiku Medicinskog fakulteta Sveučilišta u Rijeci

 Radno iskustvo

1996. – 2021. Predstojnik Zavoda za Histologiju i embriologiju, Medicinski fakultet Sveučilišta u Rijeci

1999. – 2003. Dekan, Medicinski fakultet Sveučilišta u Rijeci

 Nagrade i priznanja

Hrvatska nacionalna nagrada za znanost “Ruđer Bošković” (1993.)

Odlikovanje Redom Danice hrvatske s likom Ruđera Boškovića odlukom predsjednika Republike Hrvatske (1995.)

Godišnja nagrada Hrvatske akademije znanosti i umjetnosti za znanstvena dostignuća (2003.)

Gostujući profesor Raine Foundation na University of Western Australia (2007.)

Nagrada Akademije medicinskih znanosti Hrvatske (2009.)

Nagrada za životno djelo Republike Hrvatske u području znanosti (2013.)

Nagrada za životno djelo Grada Rijeke u području znanosti (2017.)

 Obnašanje voditeljskih i drugih dužnosti u međunarodnim i nacionalnim tijelima

Hrvatska zaklada za znanost – Upravni odbor (2010. – 2021.)

Institut za medicinska istraživanja, predsjednik Upravnog vijeća (2012. – )

Nacionalni odbor za nagrade za znanost (2016. – )

Nacionalno vijeće za znanost (1994. – 2002.)

Nacionalno vijeće za visoko obrazovanje (2000. – 2003.)

EU FP6/FP7 Programski odbor – Health (2006. – 2011.)

Znanstveno vijeće Sveučilišta u Rijeci, predsjednik (2013. – 2017.)

Leibniz Institute of Virology (bivši Heinrich Pette Institute), Znanstveni savjetodavni odbor (2016. – )

 Članstva u akademijama znanosti

2012. – Njemačka nacionalna akademija znanosti – Leopoldina

2015. – Europska mikrobiološka akademija

2021. – Academia Europea

Mentorstva

1990. – 2022.: 23 doktoranda + 11 magistara;

Mnogi bivši doktorandi i suradnici danas su sveučilišni profesori i vodeći znanstvenici u Hrvatskoj i ugledni znanstvenici u inozemstvu. Neki od njih također imaju važnu ulogu u vodstvu akademskog sektora.

 Glavna znanstvena otkrića

  1. Dokaz da su CD4-stanice i IFN-γ nužni za sprječavanje horizontalnog prijenosa infekcije mišjeg citomegalovirusa (MCMV) ( Exp. Med. 169:1199-1212, 1988; J. Virol. 66:1977-1984, 1992)
  2. Dokaz da antitijela nisu potrebna za kontrolu primarne CMV-infekcije, ali igraju ključnu ulogu u ograničavanju ponovne infekcije ( Exp. Med. 179:1713-1717, 1994)
  3. Dokaz da subpopulacije CD8- i CD4- T-stanica, IFN-γ kao i NK-stanice doprinose na hijerarhijski i redundantni način imunološkom nadzoru latencije MCMV ( Exp. Med. 188:1047-1054, 1998)
  4. Dokazi za in vivo ulogu herpesvirusnih imunoevazina uključenih u modulaciju molekula MHC klase I ( Exp. Med. 190:1285-1295, 1999) i otkrivanje i karakterizacija nekoliko MCMV-inhibitora staničnih NKG2D-liganada (Nat. Immunol. 3:529-535, 2002; J. Virol. 79:2920-30, 2005; J. Exp. Med. 201:211-220, 2005; J. Exp. Med. 203:1843-50, 2006)
  5. Uspostavljanje MCMV-modela prirođene citomegalovirusne infekcije CNS-a u razvoju ( Exp. Med. 205:423-35, 2008; J. Virol. 82(24):12172-80, 2008) – zajedno s WJ Britt, UAB, Alabama
  6. Otkriće inhibitornog receptora (TIGIT) na ljudskim NK-stanicama i nekim subpopulacijama T-stanica (PNAS USA. 106(42):17858-63, 2009) – zajedno s O. Mandelboim, Hebrew University, Jerusalem
  7. Karakterizacija mehanizama putem kojih MCMV izbjegava aktivaciju NK-stanica ovisnu o nestanku molekula MHC I ( Exp. Med. 207(12):2663-73, 2010; J. Exp. Med. 2019)
  8. Karakterizacija rekombinantnog vektorskog CMV-cjepiva koji eksprimiraju ligande za NKG2D-receptor ( Clin. Invest. 120:4532-45, 2010; PNAS USA 110:16550-5, 2013; Eur. J. Immunol. 47:1354–1367, 2017; Front. Immunol. 9:991, 2018; Front. Immunol. 12:681380, 2021)
  9. Sveobuhvatna analiza MCMV transkriptoma (PLoS Pathog. 9(9):e1003611, 2013)
  10. Dokaz da MCMV smanjuje ekspresiju PVR i utječe na kontrolu virusa upalnim monocitima i NK- stanicama na način ovisan o receptoru DNAM-1 ( Exp. Med. 213(9):1835-50, 2016)
  11. Identifikacija člana obitelji MCMV m02, m12, kao funkcionalnog liganda-mamca koji koristi mišji receptor NKRP1B i inhibira citotoksičnost NK-stanica (Cell. 169:58–71, 2017), suradnja s JR Carlyle,  University of Toronto
  12. Dokazi da NK/ILC1 stanice putem IFN-γ igraju ključnu ulogu u ranoj upali i neurorazvojnim abnormalnostima kod kongenitalno CMV-inficiranih miševa. ( Exp. Med. 3;218(5):e20201503, 2021)
  13. Karakterizacija urođenih imunoloških mehanizama u jajnicima koji štite plodnost u životinja zaraženih s virusom CMV (Immunity. 54(7):1478-1493.e6, 2021)

 Recenzije i uredništva

Urednički odbori: Cellular & Molecular Immunology – pomoćnik glavnog urednika (2017. – 2020.); Current Immunology Reviews – član uredničkog savjetodavnog odbora; European Journal of Immunology; Frontiers in Microbial Immunity; Herpesviridae; Microbes and Infections; Medical Microbiology and Immunology; eLife –urednik za recenzije ; PLOS Pathogens – gostujući urednik; Viruses – gostujući urednik, posebno izdanje

Recenzent za časopise: Blood, Cell Host & Microbe, Cell Reports, eLife, Infection and Immunity, Immunity, Nature Communication, Nature Immunology, Journal of Experimental Medicine, Journal of Virology, Medical Microbiology and Immunology, PLOS Pathogens, PLOS Biology, Science Immunology, Annual Reviews in Immunology, Journal of Clinical Investigation

Recenzent za projekte: ERC Starting grant – panel za evaluacije LS6 – Imunitet i infekcije (2014. – 2018.),

NIAID, Hrvatska zaklada za znanost, French Research Agency (FRA), Innovational Research Incentives Scheme Vidi 2012, Austrian Academy of Sciences, The German Israeli Foundation for Scientific Research and Development, European Science Foundation

Odobreni projekti

Tijekom proteklih deset godina radio je na 23 financirana projekta kao PI (11) ili Co-PI (12), uključujući Centar izvrsnosti za virusnu imunologiju i cjepiva” (CerVirVac), u kojem sudjeluju Centar za istraživanje i prijenos znanja u biotehnologiji i Klinika za infektive bolesti “Dr. Fran Mihaljević” Sveučilišta u Zagrebu te Medicnski fakultet Sveučilišta u Rijeci.

Projekti u tijeku: ”Advanced Concepts in Cellular Immune Control of Cytomegalovirus”, Deutsche Forschungsgemeinschaft (DFG), koordinator Lars Dölken i 16 partnera, 2019-2025; ”New Cytomegaloviral vaccine vector concepts”, Helmholtz European Partnering, koordinator Luka Čičin-Šain, Helmholtz Center for Infection Research; 6 partnera, 2019 – 2024; ”Inflammation and hearing loss following congenital CMV infection”, National Institutes of Health (NIH) R01, coPI: William J Britt, University of Alabama at Birmingham, USA i Stipan Jonjić, 2017 – 2022;

Zaključeni projekti (agencije): EU FP7; EU FP6; H2020 (ERC-2012-AdG StAdvInn, ERC-2018-PoC GLIOVACC, GLYCOVAX); NIH; Hrvatska zaklada za znanost; The Instrument for Pre-Accession Assistance (IPA); Zajednički istraživački program Hrvatske i Izraela; UKF Fund, i ostali. Imao je ključnu ulogu u organizaciji i provođenju projekta TransMedRi, koji je podržan od strane FP7 Capacity programa.

Akademsko poduzetništvo

Na temelju otkrića i izuma koje je napravio njegov laboratorij, zajedno s prof. Oferom Mandelboimom (Hebrejsko sveučilište Jeruzalem), u suradnji s Integra Holdings & Yissum kao ključnim dioničarima, 2017. godine osnovali su akademsku tvrtku Nectin Therapeutics (http://www.nectintx .com/). Nectin Therapeutics razvija nove terapeutike temeljene na monoklonskim antitijelima usmjerenim na članove obitelji receptora Nectina i njihove ligande, koji igraju glavnu ulogu u mehanizmima imunoloških kontrolnih točki relevantnih za imunološku terapiju raka.

 Patenti (od 15 prijavljenih)

  1. Vaccine comprising beta-herpesvirus; U.S. Pat. No. 10,537,621, odobren 01. 2021, 2020 (izumitelj)
  2. Antibodies specific to T-Cell immunoglobulin and itim domain (TIGIT); Japanese Patent No. 6861418, approved April 1, 2021 and U.S. Pat. No. 10,946,095, approved March 16, 2021 (3 izumitelja)
  3. Anti-poliovirus receptor antibodies and the use of same for the treatment of tumors; U.S. Pat. No. 10906987, odobren 02, 2021 (4 izumitelja)
  4. Anti-NKp46 antibodies, toxin conjugates, and therapeutic use of same; U.S. Patent No. 10,716,864, odobren 06. 2021, 2020 (4 izumitelja)

Organizacije znanstvenih skupova

Gotovo 30 znanstvenih skupova, uključujući: Hrvatsko-izraelski kick-off sastanak o virusnoj imunologiji i patogenezi, 2007., Rijeka; Marie Curie Ljetna škola “NK Defense and Therapy ” ; Napredni laboratorijski tečaj “Viral Subversion of Immune Response”, Howard Hughes Medical Institute, 2009., Rijeka; 12th Meeting of the Society for Natural Immunity, 2010 , Dubrovnik; Radionica o kongenitalnim infekcijama, TransMedRi, Sveučilište u Rijeci, 2012., Rijeka; Simpozij Cijepljenje i imunoterapija u obrani od zaraznih bolesti i tumora, u suorganizaciji HAZU, 2015., Rijeka; Simpozij „Virusna patogeneza i imunitet”, 10. obljetnica Centra za proteomiku, 2016., Rijeka


Bibliografija

Odabrani znanstveni radovi (50 od ukupno 230):

Citations (01.06.2022.): Web of Science: 11.245 (h-index: 56); Google Scholar: 15.986 (h-index: 66).

  1. Cokaric Brdovcak M, Materljan J, Sustic M, Ravlic S, Ruzic T, Lisnic B, Miklic K, Brizic I, Pribanic Matesic M, Juranic Lisnic V, Halassy B, Roncevic D, Knezevic Z, Stefan L, Bertoglio F, Schubert M, Cicin-Sain L, Markotic A, Jonjic S, Krmpotic A. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. European Journal of Immunology., doi: 10.1002/eji.202249823. 2022 (Impact factor (IF): 5.532)
  2. Kim Y, Zheng X, Eschke K, Chaudhry MZ, Bertoglio F, Tomic A, Krmpotic A, Hoffmann M, Bar-On Y, Boehme J, Bruder D, Ebensen T, Brunotte L, Ludwig S, Messerle M, Guzman C, Mandelboim O, Hust M, Pohlmann S, Jonjic S, Cicin-Sain L. MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cellular & Molecular Immunology, 19(2):234-244. doi: 10.1038/s41423-021-00814-5. 2022 (IF: 11.53)
  3. Ružić T, Lisnić VJ, Lučin HM, Roviš TL, Železnjak J, Brdovčak MC, Vrbanović A, Oreb D, Kveštak D, Jerčić KG, Borovečki F, Lučin P, Adler B, Jonjić S, Lisnić B. Characterization of M116.1p, a murine cytomegalovirus protein required for efficient infection of mononuclear phagocytes. Journal of Virology, doi: 10.1128/JVI.00876-21. 2021 (IF: 5.103)
  4. Tomac J, Mazor M, Lisnić B, Golemac M, Kveštak D, Bralić M, Bilić Zulle L, Brinkmann MM, Dölken L, Reinert LS, Paludan SR, Krmpotić A, Jonjić S, Juranić Lisnić V: Viral infection of the ovaries compromises pregnancy and reveals innate immune mechanisms protecting fertility. Immunity, doi: 10.1016/j.immuni.2021.04.020. 54(7):1478-1493.e6. 2021 (IF: 31.745)
  5. Kveštak D, Juranić Lisnić V, Lisnić B, Tomac J, Golemac M, Brizić I, Indenbirken D, Cokarić Brdovčak M, Bernardini G, Krstanović F, Rožmanić C, Grundhoff A, Krmpotić A, Britt WJ, Jonjić S: NK/ILC1 cells mediate neuroinflammation and brain pathology following congenital CMV infection. Journal of Experimental Medicine, doi: 10.1084/jem.20201503. 218(5):e20201503. 2021 (IF: 14.307)
  6. Chaudhry MZ, Casalegno-Garduno R, Sitnik KM, Kasmapour B, Pulm A-K, Brizic I, Eiz-Vesper B, Moosmann A, Jonjic S, Mocarski ES, Cicin-Sain L: Cytomegalovirus Inhibition of Extrinsic Apoptosis Determines Fitness and Resistance to Cytotoxic CD8 T Cells. Proceedings of the National Academy of Sciences of the United States of America, doi: 10.1073/pnas.1914667117. 117(23):12961-12968. 2020 (IF: 11.205)
  7. Berry R, Watson G, Jonjic S, Delgi-Esposti M, Rossjohn J: Modulation of Innate and Adaptive Immunity by Cytomegaloviruses. Nature Reviews in Immunology, doi:10.1038/s41577-019-0225-5. 20(2):113-127. 2020 (IF: 44.019)
  8. Železnjak J, Juranić Lisnić V, Popović B, Lisnić B, Babić M, Halenius A, L’Hernault A, Lenac Roviš T, Hengel H, Erhard F, Redwood A, Vidal S, Doelken l,  Krmpotić A, Jonjić S: The complex of MCMV proteins and MHC class I evades NK cell control and drives the evolution of virus-specific activating Ly49 receptors. Journal of Experimental Medicine, doi: 10.1084/jem.20182213. 216(8):1809-1827. 2019 (IF: 10.892)
  9. Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S: Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular and Molecular Immunology, doi: 10.1038/s41423-018-0168-y. 16(1):40-52. 2019 (IF: 8.213)
  10. Šestan M, Marinović S, Kavazović I, Cekinović Đ, Wueest S, Turk Wensveen T, Brizić I, Jonjić S, Konrad D, Wensveen FM, Polić B: Virus-Induced Interferon-γ Causes Insulin Resistance in Skeletal Muscle and Derails Glycemic Control in Obesity. Immunity, doi: 10.1016/j.immuni.2018.05.005. 49(1):164-177. 2018 (21.522)
  11. Brizić I, Šušak B, Arapović M, Huszthy PC, Hiršl L, Kveštak D, Lisnić VJ, Golemac M, Pugel EP, Tomac J, Oxenius A, Britt WJ, Arapović J, Krmpotić A, Jonjić S: Brain-resident memory CD8+ T cells induced by congenital CMV infection prevent brain pathology and virus reactivation. European Journal of Immunology, doi: 10.1002/eji.201847526. 48(6):950-964. 2018 (IF: 4.695)
  12. Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O: NKp46 Receptor-Mediated Interferon-y Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity, doi: 10.1016/j.immuni.2017.12.007. 48(1):107-119.e4. 2018 (IF: 21.522)
  13. Molgora M, Bonavita E, Ponzetta A, Riva F, Barbagallo M, Jaillon S, Popovic B, Bernardini G, Magrini E, Gianni F, Zelenay S, Jonjic S, Santoni A, Garlanda C, Mantovani A: IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity. Nature, doi:10.1038/nature24293. 551(7678):110-114. 2017 (IF: 41.577)
  14. Miletic A, Lenartic M, Popovic B, Brizic I, Trsan T, Miklic K, Mandelboim O, Krmpotic A, Jonjic S: NCR1-deficiency diminishes the generation of protective murine cytomegalovirus antibodies by limiting follicular helper T-cell maturation. European Journal of Immunology, doi: 10.1002/eji.201646763. 47(9):1443-1456. 2017 (IF: 4.248)
  15. Popovic B, Golemac M, Podlech J, Zeleznjak J, Bilic-Zulle L, Lukic M, Cicin-Sain L, Reddehase M, Sparwasser T, Krmpotic A, Jonjic S: IL-33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLOS Pathogens, doi: 10.1371/journal.ppat.1006345. 13(4):e1006345. 2017 (IF: 6.158)
  16. Aguilar AO, Berry R, Rahim MMA, Reichel JJ, Popovic B, Tanaka M, Fu Z, Balaji GR, Lau TNH, Tu MM, Kirkham CL, Mahmoud AB, Mesci A, Krmpotic A, Allan DSJ, Makrigiannis AP, Jonjic S, Rossjohn J, Carlyle JR: A Viral Immunoevasin Controls Innate Immunity by Targeting the Prototypical Natural Killer Cell Receptor Family. Cell, doi: 10.1016/j.cell.2017.03.002. 169(1):58-71.e14. 2017 (IF: 31.398)
  17. Tomic A,Varanas PR, Golemac M, Malic S, Riese P, Borst EM, Mischak-Weissinger E,  Guzmán CA, Krmpotić A, Jonjic S, Messerle M: Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. PLoS Pathogens,   doi: 10.1371/journal.ppat.1006015. 12(12):e1006015. 2016 (IF: 6.608)
  18. Lenac Rovis T,  Kucan Brlic P, Kaynan N, Juranic Lisnic V, Brizic I, Jordan S Tomic A, Kvestak D, Babic, Tsukerman P, Colonna M, Koszinowski U, Messerle M, Mandelboim O, Krmpotic A, Jonjic S: Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection. Journal of Experimental Medicine, doi: 10.1084/jem.20151899. 213(9):1835-50. 2016 (11.991)
  19. Lisnic B, Juranic Lisnic V, Jonjic S: NK cell interplay with cytomegaloviruses. Current Opinion in Virology, doi: 10.1016/j.coviro.2015.07.001. 15:9–18. 2015 (IF: 6.064)
  20. Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, Vivier E, Jonjic S, Oxenius A: Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity, doi: 10.1016/j.immuni.2014.05.003. 40(6):961-73. 2014 (IF: 21.561)
  21. Trsan T, Busche A, Abram M, Wensveen FM, Lemmermann NA, Arapovic M, Babic M,Tomic A, Golemac M, Brinkmann MM, Jäger W, Oxenius A, Polic B, Krmpotic A, Messerle M, Jonjic S: Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1γ. Proceedings of the National Academy of Sciences of the United States of America, doi: 10.1073/pnas.1310215110. 110(41):16550-5. 2013 (IF: 809)
  22. Juranic Lisnic V, Babic Cac M, Lisnic B, Trsan T, Mefferd A, Mukhopadhyay CD, Cook CH, Jonjic S, Trgovcich J: Dual analysis of the murine cytomegalovirus and host cell transcriptomes reveal new aspects of the virus-host cell interface. PLoS Pathogens, doi: 10.1371/journal.ppat.1003611. 9(9):e1003611. 2013 (IF: 8.057)
  23. Jordan S, Ruzsics Z, Mitrović M, Baranek T, Arapović J, Krmpotić A, Vivier E, Dalod M, Jonjić S, Döelken L, Koszinowski UH: Natural killer cells are required for extramedullary hematopoiesis following murine cytomegalovirus infection. Cell Host & Microbe, doi: 10.1016/j.chom.2013.04.007. 13(5):535-545. 2013 (IF:12.194)
  24. Lenac Rovis T, Bailer SM, Pothineni VR, Ouwendijk WJ, Simic H, Babic M, Miklic K, Malic S, Verweij MC, Baiker A, Gonzalez O, von Brunn A, Zimmer R, Früh K, Verjans GM, Jonjic S, Haas J: A comprehensive analysis of varicella zoster virus proteins using a new monoclonal antibody collection. Journal of Virology, 87(12):6943-6954; 2013 (IF: 4.648)
  25. van Gisbergen K, Kragten N, Hertoghs K, Wensveen F, Jonjic S, Hamann J, Nolte M, van Lier R: Mouse Hobit is a homolog of the transcriptional repressor Blimp-1 that regulates NKT cell effector differentiation. Nature Immunology, doi: 10.1038/ni.2393. 13(9):864-71. 2012 (IF:26.199)
  26. Mitrović M, Arapović J, Jordan S, Fodil-Cornu N, Ebert S, Vidal SM, Krmpotić A, Reddehase MJ, Jonjić S: The NK-cell response to mouse cytomegalovirus infection affects the level and kinetics of the early CD8(+) T-cell response. Journal of Virology, doi: 10.1128/JVI.06042-11. 86(4):2165-75. 2012 (IF:5.076)
  27. Slavuljica I, Busche A, Babić M, Mitrović M, Gasparović I, Cekinović Dj, Markova Car E, Pernjak Pugel E, Ciković A, Juranić Lisnić V, Britt WJ, Koszinowski U, Messerle M, Krmpotić A, Jonjić S: Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. Journal of Clinical Investigation, doi: 10.1172/JCI43961. 120(12):4532-45. 2010 (IF:14.152)
  28. Babic M, Pyzik M, Zafirova B, Mitrovic M, Butorac V, Lanier LL, Krmpotic A, Vidal SM Jonjic S: Cytomegalovirus immunoevasin reveals the physiological role of ”missing self” recognition in NK cell dependent virus control in vivo. Journal of Experimental Medicine, doi: 10.1084/jem.20100921.  207(12):2663-73. 2010 (IF:14.776)
  29. Lisnić VJ, Krmpotić A, Jonjić S: Modulation of natural killer cell activity by viruses. Current Opinion in Microbiology, doi: 10.1016/j.mib.2010.05.011. 13(4):530-9. 2010 (IF:7.714)
  30. Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N, Tsukerman P, Jonjic S, Mandelboim O: The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, doi: 10.1073/pnas.0903474106. 106(42):17858-63. 2009 (IF:9.432)
  31. Arapovic J, Lenac T, Antulov R, Polic B, Ruzsics Z, Carayannopoulos LN, Koszinowski UH, Krmpotic A, Jonjic S: Differential susceptibility of RAE-1 isoforms to mouse cytomegalovirus. Journal of Virology, doi: 10.1128/JVI.02549-08. 83(16):8198-207. 2009 (IF:5.150)
  32. Zafirova B, Mandarić S, Antulov R, Krmpotić A, Jonsson H, Yokoyama WM, Jonjić S, Polić B: Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity, doi: 10.1016/j.immuni.2009.06.017. 31(2):270-82. 2009 (IF:20.589)
  33. Cekinovic D, Golemac M, Pugel EP, Tomac J, Cicin-Sain L, Slavuljica I, Bradford R, Misch S, Winkler TH, Mach M, Britt WJ, Jonjic S: Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. Journal of Virology, doi: 10.1128/JVI.01214-08. 82(24):12172-80. 2008 (IF: 5.308)
  34. Jonjić S, Babić M, Polić B, Krmpotić A: Immune evasion of natural killer cells by viruses. Current Opinion in Immunology, doi: 10.1016/j.coi.2007.11.002. 20(1):30-8. 2008 (IF:455)
  35. Koontz T, Bralic M, Tomac J, Pernjak-Pugel E, Bantug G, Jonjic S, Britt WJ: Altered development of the brain after focal herpesvirus infection of the central nervous system. Journal of Experimental Medicine, doi: 10.1084/jem.20071489. 205(2):423-35. 2008 (IF:15.463)
  36. Lenac T, Budt M, Arapovic J, Hasan M, Zimmermann A, Simic H, Krmpotic A, Messerle M, Ruzsics Z, Koszinowski UH, Hengel H, Jonjic S: The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. Journal of Experimental Medicine, 203(8):1843-50. 2006 (IF:14.484)
  37. Krmpotic A, Hasan M, Loewendorf A, Saulig T, Halenius A, Lenac T, Polic B, Bubic I, Kriegeskorte A, Pernjak Pugel E, Messerle M, Hengel H, Busch D, Koszinowski UH, Jonjic S: NK cell activation through the NKG2D ligand Mult-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. Journal of Experimental Medicine, 201(2):211-220. 2005 (IF:13.965)
  38. Hasan M, Krmpotic A, Ruzsics Z, Bubic I, Lenac T, Halenius A, Loewendorf A, Messerle M, Hengel H, Jonjic S, Koszinowski UH: Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. Journal of Virology, 79(5):2920-2930. 2005 (IF:178)
  39. Bubic I, Wagner M, Krmpotic A, Saulig T, Kim S, Yokoyama WM, Jonjic S, Koszinowski UH: Gain-of-Virulence Caused by Loss of a Gene in Murine Cytomegalovirus. Journal of Virology, 78:7536-7544. 2004 (IF:398)
  40. Krmpotic A, Busch D, Bubic I, Gebhardt F, Hengel H, Hasan M, Scalzo A, Koszinowski UH, Jonjić S: MCMV glycoprotein gp40 confers virus resistance to CD8+T cells and NK cells in vivo. Nature Immunology, 3:529-35. 2002 (IF:199)
  41. Krmpotic A, Messerle M, Crnkovic-Mertens I, Polic B, Jonjic S, Koszinowski UH: The Immunoevasive Function Encoded by the Mouse Cytomegalovirus Gene m152 protects the Virus against T Cell Control in Vivo. Journal of Experimental Medicine, 190:1285-1295. 1999 (IF:214)
  42. Polic B, Hengel H, Krmpotic A, Trgovcich J, Pavic I, Lucin P, Jonjic S, Koszinowski UH: Hierarchical and Redundant Lymphocyte Subset Control Precludes Cytomegalovirus Replication during Latent Infection. Journal of Experimental Medicine, 188:1047-1054. 1998 (IF:13.214)
  43. Crnkovic-Mertens I, Messerle M, Milotic I, Szepan U, Kucic N, Krmpotic A, Jonjic S, Koszinowski UH: Virus Attenuation after Deletion of the Cytomegalovirus Fc Receptor Gene Is Not due to Antibody Control. Journal of Virology, 72(2):1377-1382. 1998 (IF:076)
  44. Jonjic S, Pavic I, Polic B, Crnkovic I, Lucin P, Koszinowski UH: Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. Journal of Experimental Medicine, 179:1713-1717. 1994 (IF:214)
  45. Lucin P, Pavic I, Polic B, Jonjic S, Koszinowski UH: Gamma interferon‑dependent clearance of cytomegalovirus infection in salivary glands. Journal of Virology, 66:1977 – 1984. 1992 (IF:5.076)
  46. Koszinowski UH, Reddehase MJ, Jonjic S: The role of CD4 and CD8 T cells in viral infections Current Opinion in Immunology, 3:471 – 475. 1991 (IF:8.771)
  47. Jonjic S, Pavic I, Lucin P, Rukavina D, Koszinowski UH: Efficacious control of cytomegalovirus infection after long‑term depletion of CD8+ T lymphocytes. Journal of Virology, 64:5457‑5464. 1990 (IF:076)
  48. Jonjic S, Mutter W, Weiland F, Reddehase MJ, Koszinowski UH: Site‑restricted persistent cytomegalovirus infection after selective long‑term depletion of CD4‑positive T lymphocytes. Journal of Experimental Medicine, 169:1199‑1212. 1989 (IF:214)
  49. Jonjic S, del Val M, Keil GM, Reddehase MJ, Koszinowski UH: A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. Journal of Virology, 62:1653‑1658. 1988 (IF:5.076)
  50. Jonjic S, Koszinowski UH: Monoclonal antibodies reactive with swine lymphocytes I. Antibodies to membrane structures that define the cytolytic T lymphocyte subset in the swine. Journal of Immunology, 133:647‑652. 1984 (IF:5.520)

Pozvana predavanja (10 od 170)

  1. Cluster of Excellence – ”From Regenerative Biology to Reconstructive Therapy”, Hannover Medical School, 2020, Hannover, Njemačka
  2. International Congress of Immunology IUIS2019, 2019, Peking, Kina
  3. 7th International Congenital CMV Conference & 17th International CMV Workshop, 2019, Birmingham, Alabama, SAD
  4. 17th Meeting of the Society for Natural Immunity NK2018, 2018, San Antonio, Texas, USA
  5. Immunology and Cancer Research Special Seminar, The Hebrew University of Jerusalem-Hadassah Medical School, 2017, Jeruzalem, Izrael
  6. 5th International Congenital CMV Conference and 15th International CMV/Betaherpesvirus Workshop, 2015,  Brisbane, Australia
  7. Immunology Seminar, Cambridge Institute for Medical Research, 2014, Cambridge, Velika Britanija
  8. NK2013 – 14th Meeting of the Society for Natural Immunity, 2013, Heidelberg, Njemačka
  9. 15th International Congress of Immunology ICI2013, 2013, Milano, Italia
  10. European Congress of Immunology, 2012, Glasgow, Škotska